2021 continues with more new launches. In this case, it is the new Xience Skypoint stent (Abbott, USA), which has just been brought to market. This is a drug-eluting stent with improvements that provide excellent navigability, as well as greater post-dilation ranges to allow treatment any type of lesion and vessel.
Xience Skypoint has maintained many of the features of the Xience family. The stent design is of an everolimus-eluting cobalt-chromium multi-link platform; its fluoropolymer coating confers exceptional clinical outcomes in terms of stent thrombosis, and it also maintains the CE mark for 1 month of dual antiplatelet therapy in patients with high bleeding risk, offering the safest stent for all indications.
Xience Skypoint has a wider expansion range than the previous Xience generation, up to 5.75 mm diameter even with a length of 48 mm. This allows for greater expansion of the stent without longitudinal shortening, which improves precision in its positioning.
Other important changes in the device are the following: a more ergonomic connector port, with the largest stent dimensions, a slimmer catheter with a seamless one-piece shaft and a slimmer profile that guarantees high pushability with minimal force, facilitating its navigability in the treatment of more challenging lesions.
Keywords: Percutaneous coronary intervention, coronary stent.
